Welcome to our dedicated page for Rezolute SEC filings (Ticker: RZLT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Rezolute’s SEC documents are packed with clinical trial data, complex R&D accounting, and frequent equity offerings—details that can overwhelm even seasoned biotech investors. If you have ever searched “Rezolute SEC filings explained simply” or wondered how Phase 2 updates hidden in an 8-K might affect cash-runway projections, this page ends the chase.
Stock Titan’s AI-powered analysis turns 200-page reports into clear takeaways. Get instant context for every Rezolute quarterly earnings report 10-Q filing, see cash burn trends visualized, and read side-by-side comparisons of trial milestones from successive 10-Ks. Real-time alerts surface Rezolute Form 4 insider transactions—so you see executive stock moves minutes after they hit EDGAR. Our platform also links each Rezolute 8-K material events explained summary to the original disclosure, letting you trace headline trial data back to the exact page.
Looking for specifics? You’ll find:
- Rezolute annual report 10-K simplified—clinical pipeline tables, risk factors, and going-concern commentary distilled into plain English.
- Rezolute executive stock transactions Form 4 and insider trading Form 4 transactions displayed with trend graphs.
- Rezolute proxy statement executive compensation insights—compare R&D milestones to bonus targets in seconds.
Whether you need Rezolute earnings report filing analysis before your next model update or are simply understanding Rezolute SEC documents with AI, our comprehensive coverage keeps you ahead. All filings, all the time—streamlined so you can focus on what matters: evaluating the science and the story behind RZLT.
Rezolute, Inc. (RZLT) reported an equity award to its Chief Medical Officer, Brian Kenneth Roberts, in a Form 4 filing. On 11/19/2025, he received 123,000 restricted stock units (RSUs)$0. These RSUs vest annually over three years, with the first portion vesting on
On the same date, he was also granted an employee stock option covering 72,000 common shares at an exercise price of
Rezolute, Inc. (RZLT) reported an equity award to its Chief Commercial Officer. On November 19, 2025, the officer received 32,000 common shares in the form of restricted stock units, granted at a price of $0. After this transaction, the officer held 59,442 common shares directly, plus 8,000 shares in an individual retirement account and 1,898 shares in a health savings account.
The filing also shows a new employee stock option grant for 19,000 options with an exercise price of $10.16 per share, expiring on November 19, 2035. The restricted stock units vest annually over three years starting on December 1, 2026, while the options vest in equal monthly installments over 36 months beginning on December 19, 2025.
Rezolute, Inc. reported new equity awards to its CEO and director, Nevan C. Elam. On 11/19/2025, he received 317,000 common shares as restricted stock units at a price of $0, increasing his beneficial ownership to 609,119 common shares held directly.
He also received an employee stock option to buy 186,000 common shares at an exercise price of $10.16 per share. These options are exercisable through 11/19/2035. The restricted stock units vest annually over three years starting on December 1, 2026, and the options vest in equal monthly installments of 1/36 beginning on December 19, 2025.
Rezolute, Inc. executive equity grants disclosed
Rezolute, Inc. reported that its Chief Financial Officer, Daron Evans, acquired 107,000 restricted stock units of Rezolute common shares on 11/19/2025 at a stated price of $0. These restricted stock units vest annually over a three-year period, with the first portion vesting on December 1, 2026.
Following this transaction, Evans beneficially owns 375,900 Rezolute common shares directly, with additional indirect holdings through family members and PoC Capital, LLC. He also received an employee stock option grant covering 63,000 Rezolute common shares at an exercise price of $10.16 per share, vesting 1/36th monthly beginning on December 19, 2025 and expiring on November 19, 2035.
Rezolute, Inc. filed a Form S-8 to cover its Amended and Restated 2021 Equity Incentive Plan, under which an aggregate of 21,950,000 shares of common stock are available for issuance. Shareholders approved the amendment to this equity plan on November 19, 2025, expanding the pool of shares that can be granted to employees, directors and other eligible participants. The filing incorporates prior S-8 registrations for the same plan and updates the total shares that may be issued as equity compensation.
Rezolute, Inc. director reports new equity awards. On 11/19/2025, a director of Rezolute, Inc. (RZLT) received 21,000 restricted stock units at a stated price of $0, increasing the director’s beneficial ownership to 58,576 common shares. The RSUs fully vest on December 1, 2026, meaning the director will receive the underlying shares only after that date if the vesting conditions are met.
The director also received a stock option grant to buy 12,000 common shares at an exercise price of $10.16 per share. These options are exercisable until November 19, 2035 and fully vest on December 1, 2026. Both awards are reported as directly owned and reflect standard equity-based compensation for board service.
Rezolute, Inc. reported an equity award to a director. A board member received 21,000 common shares in the form of restricted stock units on November 19, 2025, recorded at a price of $0, increasing their directly held stake to 114,025 common shares after the transaction. These restricted stock units fully vest on December 1, 2026.
The director was also granted a stock option covering 12,000 common shares at an exercise price of $10.16 per share, expiring on November 19, 2035. The option grant also fully vests on December 1, 2026, aligning both equity awards to the same vesting date.
Rezolute, Inc. (RZLT) reported a new equity compensation grant to one of its directors. On 11/19/2025, the reporting person acquired 21,000 common shares as a grant of restricted stock units at a price of $0, reflecting stock-based compensation rather than a purchase. After this transaction, the director beneficially owned 21,000 common shares directly.
On the same date, the director also received a stock option to buy 12,000 common shares at an exercise price of $10.16 per share, with the option expiring on 11/19/2035. Both the 21,000 restricted stock units and the 12,000 options are scheduled to fully vest on December 1, 2026, tying the director’s compensation to Rezolute’s future share performance.
Rezolute, Inc. reported results from its 2026 annual stockholder meeting. Stockholders elected all seven director nominees to the board, with each receiving a majority of votes cast. As of the record date of September 22, 2025, 90,811,368 shares of common stock were outstanding and 66,700,068 shares were represented at the meeting, establishing a quorum.
Stockholders ratified Grant Thornton LLP as independent registered public accounting firm for the fiscal year ending June 30, 2026. A non-binding say-on-pay proposal approving compensation for named executive officers also received stockholder approval. In addition, stockholders approved an amendment to the 2021 Stock Incentive Plan to increase the shares available for issuance from 14,450,000 to 21,950,000. An adjournment proposal related to the equity plan amendment was also approved but was not needed once the amendment passed.
Rezolute, Inc. (RZLT)21,000 restricted stock units at a price of $0, which fully vest on December 1, 2026. Following this grant, he directly beneficially owns 170,950 common shares. In addition, he indirectly beneficially owns 8,423,386 common shares held by Handok, Inc., for which he disclaims beneficial ownership except to the extent of any pecuniary interest.
Kim was also granted a director stock option to purchase 12,000 common shares at an exercise price of $10.16 per share, with the options fully vesting on December 1, 2026 and expiring on November 19, 2035. These awards increase his potential long‑term equity stake and further align his interests with Rezolute shareholders.
FAQ
What is the current stock price of Rezolute (RZLT)?
What is the market cap of Rezolute (RZLT)?
